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Abstract
The stem cell factor (SCF) receptor CD117 (c-kit), is widely used for identification of hematopoietic stem cells and cancer
stem cells. Moreover, CD117 expression in carcinoma cells indicates a poor prognosis in a variety of cancers. However the
potential expression in tumor microenvironment and the biological and clinical impact are currently not reported. The
expression of CD117 was immunohistochemically evaluated in a serial of 242 epithelial ovarian cancer (EOC) cases. Thirty-
eight out of 242 cases were CD117 positive in fibroblast-like stromal cells and 22 cases were positive in EOC cells. Four cases
were both positive in fibroblast-like stromal cells and EOC cells for CD117. CD117 expression in fibroblast-like stromal cells in
ovarian carcinoma was closely linked to advanced FIGO stage, poor differentiation grade and histological subtype (p,0.05),
and it was significantly associated with poor overall survival (OS) and progression free survival (PFS) (Kaplan-Meier analysis;
p,0.05, log-rank test). CD117 expression in ovarian carcinoma cells was not associated with these clinicopathological
variables. The CD117 positive fibroblast-like stromal cells were all positive for mesenchymal stem/stromal cell (MSC) marker
CD73 but negative for fibroblast markers fibroblast activation protein (FAP) and a smooth muscle actin (a-SMA), indicating
that the CD117+/CD73+ fibroblast-like stromal cells are a subtype of mesenchymal stem cells in tumor stroma, although
further characterization of these cells are needed. It is concluded herewith that the presence of CD117+/CD73+ fibroblast-
like stromal cells in ovarian carcinoma is an unfavorable clinical outcome indication.
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Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecologic
malignancy worldwide [1,2]. Most women with EOC are
diagnosed at an advanced stage. The 5-year survival is less than
30% for the women diagnosed at advanced stage [2]. Cancer stem
cells (CSCs) represent a subpopulation of tumor cells responsible
for tumor initiation, progression, invasion, metastasis and relapse,
and are capable of cell renewal. Thus, therapies targeting CSCs
are being considered a promising way to control cancer.
Tumor microenvironment is the cellular environment in which
tumor cells exist, including blood vessels, immune cells, fibroblasts,
macrophages, extracellular matrix (ECM) and other molecules,
etc. The stromal cells interact with each other in a complex net by
secreting distinct, abnormal molecules into ECM and contribute
to tumor growth and invasiveness [3,4,5,6,7]. Tumor stromal cells
from different tissue have different gene expression profiles and
hence contribute to tumor heterogeneity [8]. According to Albini,
et. al, the microenvironment of a cancer is an integral part of its
anatomy and physiology, and functionally, one cannot totally
dissociate this microenvironment from what have traditionally
been called ‘‘cancer cells’’ [9]. Therefore, it is now necessary to
develop new tumorpreventive methods to target tumor microen-
vironment and hence to interfere carcinogenesis [9].
CD117, also known as proto-oncogene c-Kit or tyrosine-protein
kinase Kit, is a transmembrane cytokine receptor expressed on the
surface of hematopoietic stem cells and other cell types. It is
normally phosphorylated and activated by binding to its ligand
stem cell factor (SCF). It is a widely used stemness marker for
recognition of cancer stem cells in various tumors, including
ovarian carcinoma, endometrial cancer, osteosarcoma [10,11,12]
and others. The unfavorable outcome for cancer patients with
CD117 expression in cancer cells is well established [10,11],
whereas, the role of CD117 expression in stromal cells is rarely
reported.
To better understand CD117 expression in ovarian carcinoma
cells and stromal cells and the clinicopathological associations, we
investigated CD117 expression in 242 formalin-fixed paraffin-
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embedded (FFPE) tumor tissue samples, which were obtained
routinely from surgical dissection of patients diagnosed with EOC
in The Norwegian Radium Hospital, Oslo University Hospital.
Furthermore, we analyzed the associations between CD117
expression and clinicopathological characters, including age,
histological subtype, differentiation grade, FIGO stage, overall
survival (OS) and progression free survival (PFS). CD117
expressions in stromal cells and tumor cells and the clinicopath-
ological analyses were investigated respectively.
Materials and Methods
Ethics Statement
The Regional Committee for Medical Research Ethics South of
Norway (S-06277a), The Social- and Health Directorate (06/
3280) and The Data Inspectorate (06/5345) approved the study.
All the patients involved provided their written consent to
participate in this study, and all the written consents were filed
in The Norwegian Radium Hospital, Oslo University Hospital.
Clinical samples
Two-hundred and forty-two surgically dissected ovarian carci-
noma samples were randomly enrolled in this study. All patients
were operated at The Norwegian Radium Hospital, Oslo
University Hospital from March 1983 to May 2001. FFPE
ovarian carcinoma tissues were obtained from the files of the
Department of Pathology, and 3mm sections were cut and used for
morphological examination and immunohistochemistry (IHC).
The ages of the patients range from 19 to 89 years, and the median
age is at 58 years old. The patients were followed up until January
1st 2012. All patients were clinically staged following the
recommendations of International Federation of Gynecology and
Obstetrics (FIGO) [13]. The primary tumors were histologically
graded as well, moderately and poorly differentiated according to
WHO recommendations [13]. Disease progression was deter-
mined based on the definitions outlined by the Gynecologic
Cancer Intergroup [14].
Immunohistochemistry (IHC)
The Dako Envision FLEX+ system (K8012; Dako, Glostrup,
Denmark) and the Dako Autostainer were used for IHC. Paraffin
sections were deparaffinized and epitopes unmasked in PT link
with high pH/low pH target retrieval solution (Dako), and then
blocked with peroxidase blocking (Dako) for 5 minutes. The slides
were incubated with primary antibody 30 minutes at room
temperature, following up with rabbit/mouse linker (Dako)
according to the resource of primary antibody for 15 minutes
and HRP for 30 minutes at room temperature. Slides were then
stained with 3, 39-diaminobenzidine tetrahydrochloride (DAB) for
10 minutes and counter-stained with hematoxylin, dehydrated,
and mounted in Richard-Allan Scientific Cyto seal XYL (Thermo
Scientific, Waltham, MA, USA). Already known each antibody
positive tissue was used as positive control in the same procedure.
The same positive control slide was used as a negative control
incubated with the same concentration of non-immune rabbit/
mouse IgG replacing the primary antibody. The information for
each primary antibody is shown in Table 1.
Table 1. The primary antibodies used for IHC.
Name Company Catalog number Resource Dilution
Retrieval
solution Positive control
CD117 Dako A4502 Rabbit 1:400 HPH Human seminoma tissue
FAP Abcam Ab53066 Rabbit 1:300 HPH Human colon tissue
a-SMA BioGenex MU128-UC Mouse 1:750 HPH Human appendix tissue
CD73 LSBio LS-C138754 Rabbit 1:1600 LPH Human tonsil tissue
doi:10.1371/journal.pone.0112209.t001
Figure 1. (A) Known CD117-positive seminoma tissue is always positive for CD117 and used as positive control in this study. (B)
Section from the same seminoma tissue is negative by incubating with the corresponding non-immune rabbit IgG in the same concentration, instead
of rabbit anti-CD117 antibody. Both pictures were taken at 2006.
doi:10.1371/journal.pone.0112209.g001
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IHC scoring system
CD117 immunodetection was evaluated and grouped as
positive and negative in carcinoma cells and stromal cells for
each slide. Slides were grouped as positive for tumor cells if over
10 percent of tumor cells were stained. Likewise, slides were
grouped as positive for stromal cells if over 10 percent of stromal
cells were stained. The morphology and immunostaining judg-
ment were confirmed by two pathologists.
Statistical analyses
SPSS software (version 18.0) was used for data analyses.
Associations between categorical variables were assessed by Chi-
square tests (Pearson and linear-by-linear as appropriate). Survival
analysis was estimated using the Kaplan-Meier method, and
groups were compared with log-rank tests. For all the analyses,
associations were considered to be significant if the p value was ,
0.05.
Results
Immunodetection of CD117 in ovarian carcinoma tissues
Generally, CD117 immunoreactivity was observed in some
EOC cells and stromal cells, including endothelial cells, fibroblast-
like stromal cells and blood cells. It was found out that out of 242
cases 38 were positive in fibroblast-like stromal cells and 22 cases
were positive for CD117 in EOC cells. Four cases were positive in
both fibroblast-like stromal cells and EOC cells. Positive control
and negative control were shown in Figure 1. CD117 immnor-
eactivity was limited to cytoplasm and membrane in both
fibroblast-like stromal cells (Figure 2) and tumor cells (Figure 3).
Nuclear staining was not observed. It was commonly observed if
possible, tumor cells in the same case were variably stained
(Figure 3B), and some cases were scattered immunostaining.
CD117 positive fibroblast-like stromal cells were further identified
by mesenchymal stem/stromal cell (MSC) marker CD73 (NT5E)
and cancer associated fibroblast (CAF) markers fibroblast activa-
tion protein (FAP) and a-smooth muscle actin (a-SMA). All
CD117 positive stromal cells were negative for both FAP and a-
SMA, but positive for CD73 (Figure 4).
CD117 expression in fibroblast-like stromal cells and
clinical impact
The associations between CD117 expression in fibroblast-like
stromal cells and the clinicopathological variables are demonstrat-
ed in Table 2. CD117 expression in fibroblast-like stromal cells
was significantly associated with late FIGO stage, poor differen-
tiation stage, and histological subtypes (p,0.05). No significant
difference was observed for age (patients diagnosed at $ 60 years
and #59 years (p=0.411)). CD117 expression in fibroblast-like
Figure 2. CD117 positive fibroblast-like stromal cells surrounding ovarian carcinoma cells were shown (A:2006, and B: 4006).
doi:10.1371/journal.pone.0112209.g002
Figure 3. Variable expression of CD117 in ovarian carcinoma cells is demonstrated. Themagnitudewas 2006for (A) and 4006for (B).
doi:10.1371/journal.pone.0112209.g003
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stromal cells was observed in 4.3% (2/46) of EOC patients in
FIGO stage I/II compared to 18.4% (36/196) of patients in FIGO
stage III/IV, and the difference is significant (p=0.019). For
histological grade, 0% (0/19) of well differentiated EOC samples
was CD117 positive in fibroblast-like stromal cells, compared to
11.3% (7/62) in moderately differentiated EOC samples and
21.1% (28/133) in poorly differentiated EOC samples. Thus,
CD117 immunoreactivity was closely associated with differentia-
tion grade (p=0.010). Ovarian serous carcinomas and the group
of undifferentiated EOC, mixed EOC and others showed more
CD117-positive fibroblast-like stromal cells than the group of
mucinous EOC, endometrial EOC and clear cell carcinoma
(p=0.012).
CD117 expression in EOC cells and clinical impact
For CD117 expression in EOC cells, we did not observe any
statistical difference in different age groups (p=0.632), FIGO stage
groups (p=0.267), differentiation grade groups (p=0.306) or
histological subtype groups (p=0.439) (Table 3).
Figure 4. Three pairs of slides stained with CD117 and CD73 for each pair were randomly picked and demonstrated. Each pair of the
slides was from the same tumor tissue in our database. CD117+ fibroblast-like stromal cells (A,C,E) were all positive for CD73 (B,D,F). (A,B,C,D) were
taken at 1006 and (E, F) were taken at 2006.
doi:10.1371/journal.pone.0112209.g004
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Survival analyses
Progression free survival (PFS) and overall survival (OS) were
used to analyze survival time in our study (Table 4). The patient
group with CD117 expression in fibroblast-like stromal cells had a
significantly shorter OS (Figure 5A) and PFS (Figure 5B) than the
patient group not expressing CD117 in fibroblast-like stromal cells.
When comparing the two patient groups with positive and
negative CD117 expression in tumor cells, we did find a trend for
Table 2. Associations between CD117 expression in fibroblast-like stromal cells and clinicopathological features (N = 242).
CD117 expression, n (%)
Total N negative positive p value
Age group 0.411
#59 121 104 (86.0) 17 (14.0)
$60 111 91 (82.0) 20 (18.0)
missing 10
FIGO stage 0.019
I+II 46 44 (95.7) 2 (4.3)
III+IV 196 160 (81.6) 36 (18.4)
Differentiation grade 0.010
well 19 19 (100) 0 (0)
moderately 62 55 (88.7) 7 (11.3)
poorly 133 105 (78.9) 28 (21.1)
missing 28
Histological subtype 0.012
serous 163 131 (80.4) 32 (19.6)
MUC+END+CLE 48 47 (97.9) 1 (2.1)
UND+MIX+others 27 23 (85.2) 4 (14.8)
missing 4
MUC, Mucinous carcinoma; END, Endometrioid carcinoma; CLE, Clear cell carcinoma; UND, Undifferentiated carcinoma; MIX, Mixed carcinoma.
doi:10.1371/journal.pone.0112209.t002
Table 3. Associations between CD117 expression in EOC cells and clinicopathological features (N= 242).
CD117 expression, n (%)
Total N negative positive p value
Age group 0.632
#59 121 109 (90.1) 12 (9.9)
$60 111 102 (91.9) 9 (8.1)
missing 10
FIGO stage 0.267
I+II 46 44 (95.7) 2 (4.3)
III+IV 196 176 (89.8) 20 (10.2)
Differentiation grade 0.306
well 19 17 (89.5) 2 (10.5)
moderately 62 59 (95.2) 3 (4.8)
poorly 133 116 (87.2) 22 (12.8)
missing 28
Histological subtype 0.439
serous 163 149 (91.4) 14 (8.6)
MUC+END+CLE 48 42 (87.5) 6 (12.5)
UND+MIX+others 27 26 (96.3) 1 (3.7)
missing 4
MUC, Mucinous tumor; END, Endometrioid carcinoma; CLE, Clear cell carcinoma; UND, Undifferenciated tumor; MIX, Mixed epithelial tumor.
doi:10.1371/journal.pone.0112209.t003
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the CD117-positive group to have a worse OS (Figure 5C) and
PFS (Figure 5D) probability, but no statistical significance was
achieved.
Discussion
In our study 9% of EOC cases expressed CD117 in carcinoma
cells, with a relatively lower positive frequency compared to 15%
positivity in ovarian serous carcinoma in a previous study [15].
Garrity and coworkers [16] have pointed out the variable
positivity using different antibodies, showing 6% positivity using
rabbit anti-human CD117 antibody from one company compared
to 33% positivity with stronger staining background using rabbit
anti-human CD117 from another antibody. In our current study,
we firstly tested 4 commercial anti-human CD117 antibodies and
chose the optimized one with high specificity and low background
staining as revealed by the previous study [17]. Further IHC
procedure optimization was performed in order to ensure high
sensitivity for this antibody as well.
CD117 is mostly reported in mast cells/myeloid cells (masto-
cytoma/acute myeloid leukemia) [18], germ cells (seminoma) [19],
Cajal cell (gastrointestinal stromal tumors) [20,21] and some
epithelial cells [22,23,24,25]. CD117 expression in tumor stromal
cells is neglected and rarely reported. In our series, we disclosed for
the first time that CD117 expression in fibroblast-like stromal cells
had a statistical association with poor clinical outcomes.
The importance of microenvironment for tumor growth is well
established [26,27,28,29]. Fibroblast cells, as predominant com-
ponent in the microenvironment, act synergistically with carcino-
ma cells to prepare the microenvironment according to the ‘‘seed
and soil’’ theory [29,30]. Fibroblasts in mammals comprise a
highly heterogeneous group of cells, and reflect a substantial
genetic diversity [31]. Similar to organ fibrosis, the fibroblasts at
the site of a carcinoma remain perpetually activated, and this
subpopulation of fibroblasts are designated cancer-associated
fibroblasts (CAFs) [32]. FAP and a-SMA are widely used among
other markers to mark CAFs in tumors. FAP is selectively
expressed on fibroblasts within the tumor stroma or on CAFs
[33,34]. a-SMA is positive in most of smooth muscle cells and
fibroblasts in the stroma of the epithelial cancer [35,36]. In our
study, the CD117+ fibroblast-like stromal cells were neither
positive for FAP nor positive for a-SMA, which shadows forth that
these morphologically fibroblast-like stromal cells were not
supposed to be fibroblasts actually.
To further identify these cells, mesenchymal stem/stromal cell
(MSC) marker CD73 (NT5E) were immune-evaluated. More
intriguingly, All CD117+ fibroblast-like stromal cells were positive
for CD73. Mesenchymal stem cells (MSCs) were initially isolated
from the bone marrow and demonstrated the multipotency to
differentiate into a variety of cell types [37,38]. MSCs recruited
into the tumors as the progenitors of stromal cells may play a
significant role in the regulation of both solid and haematological
malignancies [39]. It is still an open discussion about how to define
MSCs, because no single marker is specific to identify MSCs to
date [40]. Cultured MSCs are uniformly and strongly positive for
CD105, CD90, and CD73, regardless of their passage or time in
culture [41], and it has been one of the minimal criteria to identify
MSC [40,42]. Moreover, the morphology of MSCs was reported
to be fibroblast-like [43,44]. Bone marrow-derived MSCs selec-
tively express FAP but not other resources [45], and slightly
express a-SMA [46]. But MSCs in tumor stroma are currently not
reported to express these two markers. As a result, to our point of
view, there is a possibility for these CD117+/CD73+ fibroblast-
like stromal cells to be MSC-derived, although currently we are
not able to confirm this suppose.
The effect of MSCs on tumor growth is still controversial, but
Ljujic, et. al believes MSCs are capable to home to tumor cites and
promote tumor growth in mice [47]. CD73, also known as ecto-59-
nucleotidase, is an enzyme that in humans is encoded by the
NT5E gene and commonly serves to convert adenosine mono-
phosphate (AMP) to adenosine. Through the increasing adenosine,
CD73 contribute to immunosuppressive effects of anti-tumor T
cells [48] and regulate adaptive responses upon hypoxia[49].
Furthermore, CD73 expression in tumor cells and tumor
environment are required for tumor angiogenesis [50].The
percentage of CD73+ Natural killer (NK) NK cells increases
significantly on coculture with MSCs and thus acquires the ability
to convert AMP into adenosine [51]. Epithelial mesenchymal
transition (EMT) is a fundamental biologic process during which
epithelial cells lose their polarity and change to a mesenchymal
phenotype [52,53,54]. The mesenchymal state facilitates cells with
the capacity of migrating to distant organs and maintain stemness,
Table 4. CD117 expression and survival (years).
Mean Median p value
Extimate 95% CI Extimate 95% CI
OS:CD117 in tumor cells
Negative (n = 211) 5.649 4.494 to 6.805 1.719 1.267 to 2.172 0.113
Positive (n = 21) 2.995 0.948 to 5.041 0.715 0.000 to 1.652
OS:CD117 in fibroblast-like stromal cells
Negative (n = 195) 5.922 4.686 to 7.159 1.719 1.165 to 2.274 0.031
Positive (n = 37) 2.978 1.269 to 4.688 1.098 0.605 to 1.591
PFS:CD117 in tumor cells
Negative (n = 211) 4.592 3.405 to 5.774 0.665 0.516 to 0.814 0.204
Positive (n = 21) 2.274 0.332 to 4.217 0.216 0.000 to 0.560
PFS:CD117 in fibroblast-like stromal cells
Negative (n = 195) 4.484 3.574 to 6.105 0.706 0.483 to 0.929 0.016
Positive (n = 37) 2.180 0.415 to 3.946 0.397 0.221 to 0.573
doi:10.1371/journal.pone.0112209.t004
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allowing the initiation of metastasis [53]. CD73 may contribute to
induce EMT by the regulation of EMT-related key factors
including cadherin-1 (CDH1) and vimentin (VIM) [55].
The traditional defined MSCs, including bone marrow-derived
MSCs (BM-MSCs) and human embryonic stem cell-derived
mesenchymal stroma cells (hES-MSCs), express CD73 but rarely
express CD117 [56,57]. On the other hand, CD117 was also
regarded as one of MSC markers [11,58]. In our study, we found
that CD117 expressed in fibroblast-like stromal cells in ovarian
carcinomas was significantly linked to poor clinical characters and
survival time. Although these CD117 positive stromal cells were
negative for both fibroblast markers FAP and a-SMA, it was
confirmed in our study that these cells were positive for
mesenchymal stem cell marker CD73, which strongly indicates
their mesenchymal stem cells in nature. To the best of our
knowledge, this is the first report of CD117+/CD73+ tumor
stromal cells with negative clinical consequences.
To conclude, it is verified in our study that CD117+/CD73+
fibroblast-like stromal cells are significantly associated with poor
clinical manifestations and poor survival probability in ovarian
carcinomas, but CD117 expression in tumor cells does not show
any clinical significance. Thus, it is worthy of further study for
CD117 positive and CD73 positive stromal cells in EOCs in order
to explore their potential application in prognostic prediction and
targeting therapy.
Figure 5. The survival probabilities of CD117 expression in ovarian carcinoma cells and fibroblast-like stromal cells were
demonstrated. PFS (A) and OS (B) probabilities are shown for the group of CD117 positive and negative in fibroblast-like stromal cells. CD117
negativity in stromal cells shows a significantly better survival probabilities (p,0.05). PFS (C) and OS (D) probabilities are revealed for CD117
expression in ovarian carcinoma cells. No significant difference was observed for survival probabilities between CD117+ tumor cell group and CD117-
tumor cell group (p.0.05).
doi:10.1371/journal.pone.0112209.g005
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